antibody was added to each well to detect the captured alpha-synuclein (amino acids 118-123).
Samples were incubated with 50μl of detection antibody for 2 hours at room temperature. After washing, 200μl of streptavidin HRP was added and incubated for 1 hour at room temperature to recognize the bound biotinylated detection antibody. Samples were then washed and incubated with 100μl of chemiluminescent substrates. Plates were shaken for 10-15 seconds and read immediately by a luminometer.
Oligomeric alpha-synuclein ELISA. Solid phase human alpha-synuclein oligomer sandwich ELISA (Cat# MBS730762, Mybiosource) was performed on CSF. 50 µl of standards or CSF samples were added to the appropriate wells. 5 µl of balance solution and 100 µl of conjugate was dispensed into samples only and mixed well. Sample solution was mixed well and incubated for one hour at 37°C. After washing, samples were incubated with 50 µl substrate-A and 50 µl Substrate-B per well, including blank control well. Sample solution was incubated for 10-15 minutes at 37°C before 50 µl of stop solution was added to each well including blank control well.
To determine the Optical Density (O.D.), samples were read at 450 nm using a microplate reader.
Clinical Assessments
All participants were tested in the "ON" state less than 2 hours since the last dose of levodopa. A single rater conducted all clinical exams in all participants across all study visits and ON state was also verified with the participant and the objective report of study partner and study investigator/rater. Motor assessments were performed at baseline, 6, 12, and 15 months via PDQ39, TUG, MoCA and MDS-UPDRS. eFigure 1. Data represent the effects of 1-year nilotinib treatment on Abl activation via tyrosine phosphorylation and plasma dopamine metabolites compared to placebo. Graphs represent differences between study groups at 12 months in A). Levels of pan-tyrosine Abl (phosphorylation) in the CSF. B). Levels of Abl phosphorylation at tyrosine 412 in the CSF C). Levels of pan-tyrosine Abl (phosphorylation) in the plasma, D) Levels of Abl phosphorylation at tyrosine 412 in the plasma, E) Ratio of tyrosine412/pan-tyrosine in CSF, and F). Ratio of tyrosine412/pan-tyrosine in plasma. These data show that nilotinib has no effect on CSF or plasma Abl activity. Graphs represent plasma levels of G). HVA and, H) DOPAC indicating a significant increase in DOPAC alone. Graph I) represents the level of CSF TREM2, indicating no changes. Nilo: Nilotinib, Abl: Abelson, TREM2: Triggered Receptors on Myeloid Cells, Tyr: Tyrosine, HVA: Homovanillic Acid, DOPAC: 3,4-Dihydroxyphenylacetic acid, ABS: Absorption. eFigure 2. Clinical effects of nilotinib in PD using the Movement Disorders Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) and Parkinson's Disease Questionnaire (PDQ)-39. Graphs represent nilotinib effects versus placebo in moderately advanced PD patients tested "ON" time and receiving optimal PD-medications. A). Shows UPDRS-III motor , B). Total UPDRS I-III, and C). (PDQ)-39 summary index (SI) in placebo, 150mg nilotinib and 300 mg nilotinib groups. MDS-UPDRS: Movement Disorders Society-Unified Parkinson's Disease Rating Scale; PDQ-39, Parkinson's Disease Questionnaire-39 items, Nil: nilotinib. 
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